

1. Sales 1<sup>st</sup> quarter 2005 and 1<sup>st</sup> quarter 2004

| January – March        | 2005  | 2004  | % change |                     |
|------------------------|-------|-------|----------|---------------------|
|                        | CHF m | CHF m | In CHF   | In local currencies |
| Pharmaceuticals        | 6,155 | 5,217 | +18      | +22                 |
| Roche Prescription     | 3,859 | 3,546 | +9       | +11                 |
| Genentech Prescription | 1,341 | 923   | +45      | +54                 |
| Chugai Prescription    | 955   | 748   | +28      | +32                 |
| Diagnostics            | 1,935 | 1,908 | +1       | +4                  |
| Group                  | 8,090 | 7,125 | +14      | +17                 |

2. Quarterly local sales growth by Division in 2004 and 2005

|                        | Q2 2004<br>vs. Q2 2003 | Q3 2004<br>vs. Q3 2003 | Q4 2004<br>vs. Q4 2003 | Q1 2005<br>vs. Q1 2004 |
|------------------------|------------------------|------------------------|------------------------|------------------------|
| Pharmaceuticals        | +15                    | +17                    | +5                     | +22                    |
| Roche Prescription     | +10                    | +9                     | -2                     | +11                    |
| Genentech Prescription | +46                    | +54                    | +48                    | +54                    |
| Chugai Prescription    | +4                     | +7                     | -8                     | +32                    |
| Diagnostics            | +9                     | +6                     | +6                     | +4                     |
| Group                  | +13                    | +14                    | +6                     | +17                    |

3. Quarterly sales by Division in 2004 and 2005

| CHF millions           | Q1 2004 | Q2 2004 | Q3 2004 | Q4 2004 | Q1 2005 |
|------------------------|---------|---------|---------|---------|---------|
| Pharmaceuticals        | 5,217   | 5,430   | 5,485   | 5,563   | 6,155   |
| Roche Prescription     | 3,546   | 3,494   | 3,483   | 3,447   | 3,859   |
| Genentech Prescription | 923     | 1,129   | 1,235   | 1,235   | 1,341   |
| Chugai Prescription    | 748     | 807     | 767     | 881     | 955     |
| Diagnostics            | 1,908   | 1,971   | 1,884   | 2,064   | 1,935   |
| Group                  | 7,125   | 7,401   | 7,369   | 7,627   | 8,090   |

4. Top 20 prescription medicines sales<sup>1</sup> and local growth<sup>2</sup> in 1<sup>st</sup> quarter 2005: US, Japan and Europe/Rest of World

|                                    | Total |      | US    |      | Japan |      | Europe/RoW |      |
|------------------------------------|-------|------|-------|------|-------|------|------------|------|
|                                    | CHF m | %    | CHF m | %    | CHF m | %    | CHF m      | %    |
| MabThera/Rituxan                   | 929   | 24%  | 540   | 19%  | 40    | 7%   | 349        | 36%  |
| Neo Recormon/Epogin                | 516   | 7%   | -     | -    | 168   | 2%   | 348        | 10%  |
| Tamiflu                            | 424   | 302% | 30    | -    | 260   | 209% | 134        | 361% |
| Herceptin                          | 391   | 23%  | 153   | 19%  | 25    | 19%  | 213        | 26%  |
| CellCept                           | 370   | 4%   | 152   | -8%  | 6     | 20%  | 212        | 14%  |
| Rocephin                           | 330   | -6%  | 208   | 1%   | 15    | 33%  | 107        | -20% |
| Pegasys                            | 325   | 15%  | 109   | -9%  | 19    | 135% | 197        | 29%  |
| Avastin                            | 260   | 476% | 240   | 432% | -     | -    | 20         | -    |
| Xeloda                             | 165   | 48%  | 60    | 74%  | 6     | 41%  | 99         | 36%  |
| Xenical                            | 147   | 4%   | 25    | -1%  | -     | -    | 122        | 5%   |
| Nutropin/Protoprin                 | 110   | 7%   | 107   | 7%   | -     | -    | 3          | -5%  |
| Kytril                             | 105   | 0%   | 39    | -9%  | 28    | 14%  | 38         | 4%   |
| Copegus                            | 104   | 5%   | 43    | -28% | -     | -    | 61         | 61%  |
| Pulmozyme                          | 89    | 10%  | 52    | 16%  | -     | -    | 37         | 2%   |
| Cymevene/Valcyte                   | 86    | 2%   | 43    | -9%  | -     | -    | 43         | 19%  |
| Dilatrend                          | 83    | -19% | -     | -    | -     | -    | 83         | -19% |
| Xolair                             | 81    | 128% | 81    | 128% | -     | -    | -          | -    |
| Roaccutan/Accutane                 | 81    | -29% | 25    | -51% | -     | -    | 56         | -11% |
| Neutrogen                          | 80    | 9%   | -     | -    | 80    | 9%   | -          | -    |
| Activase/TNKase                    | 67    | 12%  | 60    | 14%  | -     | -    | 7          | -3%  |
| New products not covered in Top 20 |       |      |       |      |       |      |            |      |
| Tarceva                            | 57    | -    | 56    | -    | -     | -    | 1          | -    |
| Fuzeon                             | 50    | 68%  | 26    | 42%  |       |      | 24         | 112% |
| Raptiva                            | 28    | 283% | 28    | 283% | -     | -    | -          | -    |
| Evista                             | 16    | -    | -     | -    | 16    | -    | -          | -    |
| Renagel                            | 11    | 8%   | -     | -    | 11    | 8%   | -          | -    |

<sup>1</sup> Roche Rx, Genentech Rx and Chugai Rx combined

<sup>2</sup> versus 1<sup>st</sup> quarter 2004

5. Top 20 prescription medicines quarterly local sales growth<sup>1</sup> in 2004 and 2005

|                    | Q2 2004<br>Vs. Q2 2003 | Q3 2004<br>vs. Q3 2003 | Q4 2004<br>vs. Q4 2003 | Q1 2005<br>vs. Q1 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 29%                    | 31%                    | 20%                    | 24%                    |
| NeoRecormon/Epogin | 0%                     | -1%                    | 1%                     | 7%                     |
| Tamiflu            | 133%                   | -                      | -69%                   | 302%                   |
| Herceptin          | 24%                    | 25%                    | 25%                    | 23%                    |
| CellCept           | 14%                    | 0%                     | 3%                     | 4%                     |
| Rocephin           | -5%                    | 8%                     | -5%                    | -6%                    |
| Pegasys            | 82%                    | 48%                    | 24%                    | 15%                    |
| Avastin            | -                      | -                      | -                      | 476%                   |
| Xeloda             | -11%                   | 19%                    | 39%                    | 48%                    |
| Xenical            | -2%                    | -2%                    | -5%                    | 4%                     |
| Nutropin/Protropin | 10%                    | 7%                     | 10%                    | 7%                     |
| Kytril             | 1%                     | -1%                    | 11%                    | 0%                     |
| Copegus            | 110%                   | 43%                    | 13%                    | 5%                     |
| Pulmozyme          | 2%                     | 11%                    | 3%                     | 10%                    |
| Cymevene/Valcyte   | 13%                    | 14%                    | 26%                    | 2%                     |
| Dilatrend          | -4%                    | -10%                   | -27%                   | -19%                   |
| Xolair             | -                      | 704%                   | 230%                   | 128%                   |
| Roaccutan/Accutane | -17%                   | -59%                   | -43%                   | -29%                   |
| Neutrogen          | -3%                    | -1%                    | 7%                     | 9%                     |
| Activase/TNKase    | 8%                     | 13%                    | 5%                     | 12%                    |

<sup>1</sup> Roche Rx, Genentech Rx and Chugai Rx combined

6. Prescription medicines quarterly local sales growth<sup>1</sup> US in 2004 and 2005

|                    | Q2 2004<br>vs. Q2 2003 | Q3 2004<br>vs. Q3 2003 | Q4 2004<br>vs. Q4 2003 | Q1 2005<br>vs. Q1 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 16%                    | 17%                    | 8%                     | 19%                    |
| NeoRecormon/Epogin | -                      | -                      | -                      | -                      |
| Tamiflu            | 246%                   | -                      | -72%                   | -                      |
| Herceptin          | 19%                    | 19%                    | 18%                    | 19%                    |
| CellCept           | 12%                    | -15%                   | -7%                    | -8%                    |
| Rocephin           | -4%                    | 20%                    | 5%                     | 1%                     |
| Pegasys            | 26%                    | 1%                     | -3%                    | -9%                    |
| Avastin            | -                      | -                      | -                      | 432%                   |
| Xeloda             | -44%                   | 7%                     | 72%                    | 74%                    |
| Xenical            | -29%                   | -36%                   | -37%                   | -1%                    |
| Nutropin/Protropin | 10%                    | 7%                     | 11%                    | 7%                     |
| Kytril             | -6%                    | -6%                    | 20%                    | -9%                    |
| Copegus            | 47%                    | -2%                    | -24%                   | -28%                   |
| Pulmozyme          | 3%                     | 14%                    | 5%                     | 16%                    |
| Cymevene/Valcyte   | 4%                     | 6%                     | 35%                    | -9%                    |
| Dilatrend          | -                      | -                      | -                      | -                      |
| Xolair             | -                      | 704%                   | 230%                   | 128%                   |
| Roaccutan/Accutane | -31%                   | -                      | -70%                   | -51%                   |
| Neutrogen          | -                      | -                      | -                      | -                      |
| Activase/TNKase    | 10%                    | 15%                    | 6%                     | 14%                    |

<sup>1</sup> Roche Rx and Genentech Rx combined

7. Prescription medicines quarterly local sales growth Japan<sup>1</sup> in 2004 and 2005

|                    | Q2 2004<br>vs. Q2 2003 | Q3 2004<br>vs. Q3 2003 | Q4 2004<br>vs. Q4 2003 | Q1 2005<br>vs. Q1 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 123%                   | 120%                   | 15%                    | 7%                     |
| NeoRecormon/Epogin | -5%                    | -2%                    | 0%                     | 2%                     |
| Tamiflu            | -                      | -                      | -87%                   | 209%                   |
| Herceptin          | 3%                     | 11%                    | 18%                    | 19%                    |
| CellCept           | 14%                    | 17%                    | 20%                    | 20%                    |
| Rocephin           | -11%                   | 1%                     | 2%                     | 33%                    |
| Pegasys            | -                      | -                      | 1190%                  | 135%                   |
| Avastin            | -                      | -                      | -                      | -                      |
| Xeloda             | 484%                   | 48%                    | 28%                    | 41%                    |
| Xenical            | -                      | -                      | -                      | -                      |
| Nutropin/Protropin | -                      | -                      | -                      | -                      |
| Kytril             | -8%                    | -6%                    | 0%                     | 14%                    |
| Copegus            | -                      | -                      | -                      | -                      |
| Pulmozyme          | -                      | -                      | -                      | -                      |
| Cymevene/Valcyte   | -                      | -                      | -                      | -                      |
| Dilatrend          | -                      | -                      | -                      | -                      |
| Xolair             | -                      | -                      | -                      | -                      |
| Roaccutan/Accutane | -                      | -                      | -                      | -                      |
| Neutrogen          | -3%                    | -1%                    | 7%                     | 9%                     |
| Activase/TNKase    | -                      | -                      | -                      | -                      |

<sup>1</sup> Chugai Rx

8. Prescription medicines quarterly local sales growth Europe/Rest of World<sup>1</sup> in 2004 and 2005

|                    | Q2 2004<br>vs. Q2 2003 | Q3 2004<br>vs. Q3 2003 | Q4 2004<br>vs. Q4 2003 | Q1 2005<br>vs. Q1 2004 |
|--------------------|------------------------|------------------------|------------------------|------------------------|
| MabThera/Rituxan   | 52%                    | 55%                    | 51%                    | 36%                    |
| NeoRecormon/Epogin | 4%                     | 0%                     | 2%                     | 10%                    |
| Tamiflu            | 278%                   | -                      | 103%                   | 361%                   |
| Herceptin          | 33%                    | 34%                    | 34%                    | 26%                    |
| CellCept           | 16%                    | 17%                    | 14%                    | 14%                    |
| Rocephin           | -6%                    | -10%                   | -22%                   | -20%                   |
| Pegasys            | 130%                   | 87%                    | 33%                    | 29%                    |
| Avastin            | -                      | -                      | -                      | -                      |
| Xeloda             | 27%                    | 28%                    | 23%                    | 36%                    |
| Xenical            | 7%                     | 8%                     | 5%                     | 5%                     |
| Nutropin/Protopin  | 3%                     | -2%                    | 4%                     | -5%                    |
| Kytril             | 21%                    | 12%                    | 9%                     | 4%                     |
| Copegus            | 367%                   | 275%                   | 120%                   | 61%                    |
| Pulmozyme          | 1%                     | 5%                     | 1%                     | 2%                     |
| Cymevene/Valcyte   | 27%                    | 25%                    | 15%                    | 19%                    |
| Dilatrend          | -4%                    | -10%                   | -27%                   | -19%                   |
| Xolair             | -                      | -                      | -                      | -                      |
| Roaccutan/Accutane | -3%                    | -9%                    | -21%                   | -11%                   |
| Neutrogen          | -                      | -                      | -                      | -                      |
| Activase/TNKase    | -4%                    | -3%                    | -5%                    | -3%                    |

<sup>1</sup> Roche Rx

9. Top Prescription medicines quarterly sales<sup>1</sup> in 2004 and 2005

| CHF millions                              | Q1 2004 | Q2 2004 | Q3 2004 | Q4 2004 | Q1 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan                          | 782     | 842     | 877     | 877     | 929     |
| NeoRecormon/Epogin                        | 489     | 531     | 528     | 534     | 516     |
| Tamiflu                                   | 108     | 19      | 110     | 93      | 424     |
| Herceptin                                 | 328     | 356     | 373     | 378     | 391     |
| CellCept                                  | 369     | 350     | 337     | 347     | 370     |
| Rocephin                                  | 369     | 305     | 307     | 321     | 330     |
| Pegasys                                   | 289     | 295     | 296     | 299     | 325     |
| Avastin                                   | 48      | 169     | 235     | 238     | 260     |
| Xeloda                                    | 115     | 128     | 145     | 146     | 165     |
| Xenical                                   | 146     | 165     | 145     | 137     | 147     |
| Nutropin/Protropin                        | 109     | 116     | 110     | 113     | 110     |
| Kytril                                    | 109     | 111     | 114     | 123     | 105     |
| Copegus                                   | 102     | 97      | 97      | 87      | 104     |
| Pulmozyme                                 | 84      | 82      | 86      | 86      | 89      |
| Cymevene/Valcyte                          | 86      | 79      | 81      | 83      | 86      |
| Dilatrend                                 | 104     | 96      | 86      | 75      | 83      |
| Xolair                                    | 38      | 55      | 68      | 73      | 81      |
| Roaccutan/Accutane                        | 116     | 94      | 43      | 63      | 81      |
| Neutrogen                                 | 76      | 80      | 81      | 85      | 80      |
| Activase/TNKase                           | 63      | 72      | 76      | 64      | 67      |
| <b>New products not covered in Top 20</b> |         |         |         |         |         |
| Tarceva                                   | -       | -       | -       | 17      | 57      |
| Fuzeon                                    | 31      | 47      | 43      | 47      | 50      |
| Raptiva                                   | 8       | 17      | 23      | 22      | 28      |
| Evista                                    | -       | 17      | 6       | 15      | 16      |
| Renagel                                   | 11      | 11      | 11      | 12      | 11      |

<sup>1</sup> Roche Rx, Genentech Rx and Chugai Rx combined

10. Prescription medicines quarterly sales<sup>1</sup> in US in 2004 and 2005

| CHF millions                              | Q1 2004 | Q2 2004 | Q3 2004 | Q4 2004 | Q1 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan                          | 484     | 514     | 531     | 514     | 540     |
| NeoRecormon/Epogin                        | -       | -       | -       | -       | -       |
| Tamiflu                                   | -8      | 8       | 47      | 42      | 30      |
| Herceptin                                 | 136     | 151     | 159     | 149     | 153     |
| CellCept                                  | 176     | 158     | 147     | 157     | 152     |
| Rocephin                                  | 219     | 179     | 191     | 207     | 208     |
| Pegasys                                   | 127     | 109     | 112     | 110     | 109     |
| Avastin                                   | 48      | 169     | 230     | 230     | 240     |
| Xeloda                                    | 36      | 44      | 55      | 56      | 60      |
| Xenical                                   | 27      | 29      | 20      | 20      | 25      |
| Nutropin/Protropin                        | 106     | 113     | 107     | 110     | 107     |
| Kytril                                    | 46      | 42      | 46      | 52      | 39      |
| Copegus                                   | 64      | 53      | 53      | 40      | 43      |
| Pulmozyme                                 | 48      | 46      | 50      | 51      | 52      |
| Cymevene/Valcyte                          | 51      | 42      | 44      | 47      | 43      |
| Dilatrend                                 | -       | -       | -       | -       | -       |
| Xolair                                    | 38      | 55      | 68      | 73      | 81      |
| Roaccutan/Accutane                        | 53      | 39      | -3      | 13      | 25      |
| Neutrogen                                 | -       | -       | -       | -       | -       |
| Activase/TNKase                           | 56      | 63      | 67      | 56      | 60      |
| <b>New products not covered in Top 20</b> |         |         |         |         |         |
| Tarceva                                   | -       | -       | -       | 17      | 56      |
| Fuzeon                                    | 20      | 30      | 25      | 28      | 26      |
| Raptiva                                   | 8       | 17      | 23      | 22      | 28      |
| Evista                                    | -       | -       | -       | -       | -       |
| Renagel                                   | -       | -       | -       | -       | -       |

<sup>1</sup> Roche Rx and Genentech Rx combined

11. Prescription medicines quarterly sales<sup>1</sup> in Japan in 2004 and 2005

| CHF millions                              | Q1 2004 | Q2 2004 | Q3 2004 | Q4 2004 | Q1 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan                          | 39      | 48      | 49      | 58      | 40      |
| NeoRecormon/Epogin                        | 171     | 203     | 199     | 220     | 168     |
| Tamiflu                                   | 87      | -3      | -       | 15      | 260     |
| Herceptin                                 | 22      | 26      | 28      | 31      | 25      |
| CellCept                                  | 5       | 6       | 6       | 7       | 6       |
| Rocephin                                  | 11      | 14      | 12      | 16      | 15      |
| Pegasys                                   | 8       | 18      | 22      | 25      | 19      |
| Avastin                                   | -       | -       | -       | -       | -       |
| Xeloda                                    | 4       | 6       | 6       | 8       | 6       |
| Xenical                                   | -       | -       | -       | -       | -       |
| Nutropin/Protropin                        | -       | -       | -       | -       | -       |
| Kytril                                    | 26      | 32      | 31      | 37      | 28      |
| Copegus                                   | -       | -       | -       | -       | -       |
| Pulmozyme                                 | -       | -       | -       | -       | -       |
| Cymevene/Valcyte                          | -       | -       | -       | -       | -       |
| Dilatrend                                 | -       | -       | -       | -       | -       |
| Xolair                                    | -       | -       | -       | -       | -       |
| Roaccutan/Accutane                        | -       | -       | -       | -       | -       |
| Neutrogen                                 | 76      | 80      | 81      | 85      | 80      |
| Activase/TNKase                           | -       | -       | -       | -       | -       |
| <b>New products not covered in Top 20</b> |         |         |         |         |         |
| Tarceva                                   | -       | -       | -       | -       | -       |
| Fuzeon                                    | -       | -       | -       | -       | -       |
| Raptiva                                   | -       | -       | -       | -       | -       |
| Evista                                    | -       | 17      | 6       | 15      | 16      |
| Renagel                                   | 11      | 11      | 11      | 12      | 11      |

<sup>1</sup> Chugai Rx

12. Prescription medicines quarterly sales in Europe/Rest of World<sup>1</sup> in 2004 and 2005

| CHF millions                              | Q1 2004 | Q2 2004 | Q3 2004 | Q4 2004 | Q1 2005 |
|---|---------|---------|---------|---------|---------|
| MabThera/Rituxan                          | 259     | 280     | 297     | 305     | 349     |
| NeoRecormon/Epogin                        | 318     | 328     | 329     | 314     | 348     |
| Tamiflu                                   | 29      | 14      | 63      | 36      | 134     |
| Herceptin                                 | 170     | 179     | 186     | 198     | 213     |
| CellCept                                  | 188     | 186     | 184     | 183     | 212     |
| Rocephin                                  | 139     | 112     | 104     | 98      | 107     |
| Pegasys                                   | 154     | 168     | 162     | 164     | 197     |
| Avastin                                   | -       | -       | 5       | 8       | 20      |
| Xeloda                                    | 75      | 78      | 84      | 82      | 99      |
| Xenical                                   | 119     | 136     | 125     | 117     | 122     |
| Nutropin/Protropin                        | 3       | 3       | 3       | 3       | 3       |
| Kytril                                    | 37      | 37      | 37      | 34      | 38      |
| Copegus                                   | 38      | 44      | 44      | 47      | 61      |
| Pulmozyme                                 | 36      | 36      | 36      | 35      | 37      |
| Cymevene/Valcyte                          | 35      | 37      | 37      | 36      | 43      |
| Dilatrend                                 | 104     | 96      | 86      | 75      | 83      |
| Xolair                                    | -       | -       | -       | -       | -       |
| Roaccutan/Accutane                        | 63      | 55      | 46      | 50      | 56      |
| Neutrogen                                 | -       | -       | -       | -       | -       |
| Activase/TNKase                           | 7       | 9       | 9       | 8       | 7       |
| <b>New products not covered in Top 20</b> |         |         |         |         |         |
| Tarceva                                   | -       | -       | -       | -       | 1       |
| Fuzeon                                    | 11      | 17      | 18      | 19      | 24      |
| Raptiva                                   | -       | -       | -       | -       | -       |
| Evista                                    | -       | -       | -       | -       | -       |
| Renagel                                   | -       | -       | -       | -       | -       |

<sup>1</sup> Roche Rx